Add this topic to your myFT Digest for news straight to your inbox
There’s one born every minute
Teams from the Judge and Saïd business schools tackle the issue of designer foods
Hormone is Wall Street’s new drug of choice
Companies beginning to see uptick in services
It has other products in its pipeline to go along with one that dominates the market
Financials up on Morgan Stanley and BNY earnings
An unpopular pharma segment could have dragged on the whole company’s valuation
There may be drug companies worth buying but predicting a sector recovery would be hubris
Court battles loom as drugmakers’ relationship with doctors comes under scrutiny
International Edition